SlideShare une entreprise Scribd logo
1  sur  38
Prime Diagnostics
Screening Program
Our commitment to being recognized as the most innovating, quality and consumer-
oriented distribution company of in vitro diagnostics products of Brazilian and
international markets, leads us to a strategy that includes the approval of ANVISA¹ on all
equipment and products offered to the market by Prime Diagnostics.
Our suppliers have the main international certifications (ISO9001, ISO13485, GMP-Good
Manufacturing Practices, etc.), fact that allows us to satisfy completely, or even exceed,
the requirements of the market.
(1) - ANVISA – Agência Nacional de Vigilância Sanitária (Vinculada ao Ministério da Saúde) (National Health
Surveillance Agency (linked to the Ministry of Health)
Mission
21
● General Population Screening Tests
● Hepatitis B
● Hepatitis C
● Syphilis
● HIV
Our Business
Human blood samples collected on
filter paper S&S 903
● Concept: Screening of large populations;
● Objective: 100% of the entire population;
● Methodology: Sample of dried blood collected on paper
filter (ELISA).
Business Philosophy
Aiming at:
Facilitating access to patients
Identifying epidemiological profile
Procedure for collecting blood on paper filter
See attached sample
Access Practicality Prevention Innovation Economy
Benefits
Access Practicality Prevention Innovation Economic
• Internalization of the Epidemic
• Limited need of laboratory infrastructure in remote areas
• Paper filter takes the laboratory structure of urban
centers that are difficult to access.
Benefits
• Easy method of sample collection
-Total blood
•Great solid support for antibodies
•Low volume and little invasive
•(50ul/spot)
•Transport (non-infectious)
• Easy storage at room temperature
• great stability
Access Practicality Prevention Innovation Economic
Benefits
Access Practicality Prevention Innovation Economic
•Facilitates the diagnosis and consequently:
• Immediate treatment and reduction of
severe cases
• Increasing opportunities of
prevention
• Decrease in costs with
assistance
Benefits
Access Practicality Prevention Innovation Economic
• This methodology can be integrated:
•Urban, rural and remote population
•Family health program
Benefits
Benefits
Access Practicality Prevention Innovation Economy
• Cost Savings
Transportation
Storage
Equipment
Material
- Syringe needle
-Collection tubes
- Energy (no spin)
Logistics Serum Paper Filter
Extraction Syringe Lancet
Preparation Centrifugal machine -
Conservation
Controlled Temperature
(Ice)
Environment
Transportation
Polystyrene
(Ice) Envelope
Professional Professionals Simple Training
The Benefits of Paper Filter vs. the Serum Method
1. Samples of dried blood on filter paper are easy to collect, carry and store.
2. Results equivalent to those obtained using the alternative method of test on
serum.
3. Excellent solution for areas without structure, or with precarious laboratory
structure.
4. Studies conducted by Brazilian institutions showed that, unlike the
collection method on needles, dried blood samples on paper filter remain
keep their properties preserved at extreme temperature conditions as
51°C, even when combined with high humidity.
Summary
HIV infection in the population is a growing
problem, especially in developing countries
hit by the AIDS epidemic.
The most frequent way of a child to
acquire HIV infection is through his/her
mother during pregnancy, at birth or
through breastfeeding.
The Importance of Prevention
In the 21st century, the HIV epidemic continues out
of control in many countries of the world. The Joint
United Nations Program on HIV/AIDS (UNAIDS)
estimates that 40 million people would be living with
HIV/AIDS, five million are infected every year, of
which three million would be children; of these, 500
thousand children would die as a result of the
infection and 700 thousand would have acquired
new infections only that year, many of them taken to
death before reaching adolescence.
The Importance of Prevention
Whatever the disease, it is always better to identify it in the pre-
symptomatic phase or in its early stages. This is the reason why the
programs aimed at the prevention and early diagnosis of various
diseases are the main objectives of current health initiatives. The main
purpose of these educational and prevention initiatives is to provide all
the resources necessary to disclose the information required for the
reduction of infection and mortality rates.
For example, the treatment of syphilis, a disease that can cause
blindness or death in neonates, can be accomplished with a single dose
of Benzathine Penicillin in primary cases, or up to 3 doses (one per
week), in cases of secondary or latent syphilis.
The Importance of Prevention
These initiatives can be applied to:
• General Screening Programs: For men and women in screening
diseases, such as AIDS, Syphilis and Hepatitis B and C.
The Importance of Prevention
The importance of diagnostic tests for the detection of infectious diseases,
has been widely disclosed around the world.
Programs with this scope of coverage, given their magnitude, only would be
possible to be implemented with the use of paper filter for the collection of
samples.
The Importance of Prevention
Infectious Disease Screening Program for the Population
What Prime Provides:
Prime Diagnostics has been operating in
the Brazilian market for more than five
years, and has extensive knowledge and
experience in the implementation,
management and control of population
screening programs intended for the
detection of infectious diseases.
Infectious Disease Screening Program
What Prime Provides:
1-Automated and/or semi-automated equipment:
High-tech equipment for the processing of results properly
certified at the major world sanitation control agencies such as the FDA and CE.
All equipment will be transferred under the lending scheme (commodato),
without additional cost to the program.
2 - Technical Assistance for the maintenance and repair of equipment.
Alternatives to
1 - Automated and/or semi-automated equipment:
2 – Technical Assistance
Alternative consists of hiring a laboratory to conduct the tests and the same will be paid
by PRIME.
Infectious Disease Screening Program for the Population
What Prime Provides:
4- Collection kit
All the material necessary to the collection of blood samples (model attached).
1 - Lancet
2- Sachet Silica
3- Sachet Alcohol
4– Paper filter
5– Collecting card
6- Manual
7- Small envelope
8- Larger envelope
Infectious Disease Screening Program for the
Population
• 5 - Operational Training of Sample Collection:
Training of multipliers of the process in relation to the care
and use of the material provided for the collection, storage,
handling and transport of samples.
Infectious Disease Screening Program for the Population
What Prime Provides:
6 – Chemical and Biological Reagents: Reagents needed for the processing of samples,
tested and approved by international agencies of sanitary control.
What Prime Provides:
7 - Web-based management program:
Program for remote access to web-based results, with access protected by individual
password. (model attached)
Login l (lowercase L) 970
Password: bio970
Infectious Disease Screening Program for the Population
See example attached
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
RECORDS AT ANVISA
APPROVAL IN SOUTH AFRICA
APPROVAL IN SOUTH AFRICA
APPROVAL IN SOUTH AFRICA
APPROVAL IN SOUTH AFRICA

Contenu connexe

Tendances

Global and national response to AMR
Global and national response to AMRGlobal and national response to AMR
Global and national response to AMRMurdoch University
 
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
 
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...ipposi
 
PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012erikanature
 
ABCs in EIDs: Preparing for Emerging Infectious Diseases
ABCs in EIDs:  Preparing for Emerging Infectious DiseasesABCs in EIDs:  Preparing for Emerging Infectious Diseases
ABCs in EIDs: Preparing for Emerging Infectious DiseasesArthur Dessi Roman
 
Clinical Trials During COVID-19
Clinical Trials During COVID-19Clinical Trials During COVID-19
Clinical Trials During COVID-19EMMAIntl
 
Pharmacovigilance
Pharmacovigilance Pharmacovigilance
Pharmacovigilance kiran pala
 

Tendances (19)

WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
 
Busting the myths in infection control
Busting the myths in infection control Busting the myths in infection control
Busting the myths in infection control
 
Epidemiology and Hand Hygiene
Epidemiology and Hand HygieneEpidemiology and Hand Hygiene
Epidemiology and Hand Hygiene
 
Evidence-based Practice in Infection Control and Prevention
Evidence-based Practice in Infection Control and PreventionEvidence-based Practice in Infection Control and Prevention
Evidence-based Practice in Infection Control and Prevention
 
FUNCTIONING OF INFECTION CONTROL COMMITTEE
         FUNCTIONING OF INFECTION CONTROL COMMITTEE         FUNCTIONING OF INFECTION CONTROL COMMITTEE
FUNCTIONING OF INFECTION CONTROL COMMITTEE
 
Infection control in modern hospitals
Infection control in modern hospitalsInfection control in modern hospitals
Infection control in modern hospitals
 
Global and national response to AMR
Global and national response to AMRGlobal and national response to AMR
Global and national response to AMR
 
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
 
Not All that Gets Viral is Gold
Not All that Gets Viral is GoldNot All that Gets Viral is Gold
Not All that Gets Viral is Gold
 
National Standards in Infection Control for Healthcare Facilities
National Standards in Infection Control for Healthcare FacilitiesNational Standards in Infection Control for Healthcare Facilities
National Standards in Infection Control for Healthcare Facilities
 
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...
Patients Driving Health Innovation - Dr Abaigeal Jackson CF Registry - Octobe...
 
PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012
 
Hospital committees
Hospital committeesHospital committees
Hospital committees
 
Disinfection of Probes - PHICS 2019
Disinfection of Probes - PHICS 2019Disinfection of Probes - PHICS 2019
Disinfection of Probes - PHICS 2019
 
ABCs in EIDs: Preparing for Emerging Infectious Diseases
ABCs in EIDs:  Preparing for Emerging Infectious DiseasesABCs in EIDs:  Preparing for Emerging Infectious Diseases
ABCs in EIDs: Preparing for Emerging Infectious Diseases
 
Clinical Trials During COVID-19
Clinical Trials During COVID-19Clinical Trials During COVID-19
Clinical Trials During COVID-19
 
IPSG 10 Goals
IPSG 10 Goals IPSG 10 Goals
IPSG 10 Goals
 
Pharmacovigilance
Pharmacovigilance Pharmacovigilance
Pharmacovigilance
 
Ich gcp
Ich gcpIch gcp
Ich gcp
 

Similaire à Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)

Lecture 10 : Animal Diseases
Lecture 10 : Animal DiseasesLecture 10 : Animal Diseases
Lecture 10 : Animal DiseasesWiseAcademy
 
UK Diagnostics Summit Presentations
UK Diagnostics Summit PresentationsUK Diagnostics Summit Presentations
UK Diagnostics Summit PresentationsScott Buckler
 
What's new in the uk nsc
What's new in the uk nscWhat's new in the uk nsc
What's new in the uk nscPHEScreening
 
Earli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnEarli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnAllison Littlejohn
 
Workshop 3 - "Feedback from the 15 National Conferences on Registries"
Workshop 3 - "Feedback from the 15 National Conferences on Registries" Workshop 3 - "Feedback from the 15 National Conferences on Registries"
Workshop 3 - "Feedback from the 15 National Conferences on Registries" EURORDIS - Rare Diseases Europe
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesDr Ghaiath Hussein
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Update on animal health component 1.1
Update on animal health component 1.1Update on animal health component 1.1
Update on animal health component 1.1ILRI
 
The power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemThe power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemHealth Informatics New Zealand
 
176482 633754879714110000
176482 633754879714110000176482 633754879714110000
176482 633754879714110000guestabde8b
 
RespiDx: The Respimometer Diagnostic Aid for Childhood Pneumonia
RespiDx: The Respimometer Diagnostic Aid for Childhood PneumoniaRespiDx: The Respimometer Diagnostic Aid for Childhood Pneumonia
RespiDx: The Respimometer Diagnostic Aid for Childhood PneumoniaLeith Greenslade
 
OS16 - 1.4.a Encouraging the Use of Vaccination-To-Live as a Control Strate...
OS16 - 1.4.a   Encouraging the Use of Vaccination-To-Live as a Control Strate...OS16 - 1.4.a   Encouraging the Use of Vaccination-To-Live as a Control Strate...
OS16 - 1.4.a Encouraging the Use of Vaccination-To-Live as a Control Strate...EuFMD
 
Diagnostic Testing Conference 2020
Diagnostic Testing Conference 2020Diagnostic Testing Conference 2020
Diagnostic Testing Conference 20204 All of Us
 

Similaire à Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103) (20)

Bio Oxford
Bio OxfordBio Oxford
Bio Oxford
 
Lecture 10 : Animal Diseases
Lecture 10 : Animal DiseasesLecture 10 : Animal Diseases
Lecture 10 : Animal Diseases
 
UK Diagnostics Summit Presentations
UK Diagnostics Summit PresentationsUK Diagnostics Summit Presentations
UK Diagnostics Summit Presentations
 
What's new in the uk nsc
What's new in the uk nscWhat's new in the uk nsc
What's new in the uk nsc
 
Earli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnEarli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohn
 
Earli19
Earli19Earli19
Earli19
 
Workshop 3 - "Feedback from the 15 National Conferences on Registries"
Workshop 3 - "Feedback from the 15 National Conferences on Registries" Workshop 3 - "Feedback from the 15 National Conferences on Registries"
Workshop 3 - "Feedback from the 15 National Conferences on Registries"
 
NIHR partnering with industry
NIHR partnering with industryNIHR partnering with industry
NIHR partnering with industry
 
Covid19: Essentials for the Pharmacy Technician
Covid19: Essentials for the Pharmacy TechnicianCovid19: Essentials for the Pharmacy Technician
Covid19: Essentials for the Pharmacy Technician
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseases
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
Nosocomial 2.pptx
Nosocomial 2.pptxNosocomial 2.pptx
Nosocomial 2.pptx
 
Cancer ctrl prevention
Cancer ctrl preventionCancer ctrl prevention
Cancer ctrl prevention
 
Update on animal health component 1.1
Update on animal health component 1.1Update on animal health component 1.1
Update on animal health component 1.1
 
The power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemThe power of information: Achieving a national infection management system
The power of information: Achieving a national infection management system
 
176482 633754879714110000
176482 633754879714110000176482 633754879714110000
176482 633754879714110000
 
Control of STD.pdf
Control of STD.pdfControl of STD.pdf
Control of STD.pdf
 
RespiDx: The Respimometer Diagnostic Aid for Childhood Pneumonia
RespiDx: The Respimometer Diagnostic Aid for Childhood PneumoniaRespiDx: The Respimometer Diagnostic Aid for Childhood Pneumonia
RespiDx: The Respimometer Diagnostic Aid for Childhood Pneumonia
 
OS16 - 1.4.a Encouraging the Use of Vaccination-To-Live as a Control Strate...
OS16 - 1.4.a   Encouraging the Use of Vaccination-To-Live as a Control Strate...OS16 - 1.4.a   Encouraging the Use of Vaccination-To-Live as a Control Strate...
OS16 - 1.4.a Encouraging the Use of Vaccination-To-Live as a Control Strate...
 
Diagnostic Testing Conference 2020
Diagnostic Testing Conference 2020Diagnostic Testing Conference 2020
Diagnostic Testing Conference 2020
 

Plus de Terra Vivos

VivosSouthAmerica
VivosSouthAmericaVivosSouthAmerica
VivosSouthAmericaTerra Vivos
 
vivossurvivalreport
vivossurvivalreportvivossurvivalreport
vivossurvivalreportTerra Vivos
 
Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012
Validation of the Q - Preven HIV 1   2 DBS Immunoenzyme Kit REPORT FIN 11012012Validation of the Q - Preven HIV 1   2 DBS Immunoenzyme Kit REPORT FIN 11012012
Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012Terra Vivos
 
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOAPRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOTerra Vivos
 
Reflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaReflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaTerra Vivos
 
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Terra Vivos
 
Consultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouConsultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouTerra Vivos
 
Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Terra Vivos
 
Company formation ..directives
Company formation ..directivesCompany formation ..directives
Company formation ..directivesTerra Vivos
 
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Terra Vivos
 
Professional profile ase review
Professional profile ase reviewProfessional profile ase review
Professional profile ase reviewTerra Vivos
 
Sales Projection --Bio Oxford
Sales Projection --Bio OxfordSales Projection --Bio Oxford
Sales Projection --Bio OxfordTerra Vivos
 
Revista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsRevista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsTerra Vivos
 
Prime diagnostics
Prime diagnosticsPrime diagnostics
Prime diagnosticsTerra Vivos
 
Apresentação prime 092009_ing
Apresentação prime 092009_ingApresentação prime 092009_ing
Apresentação prime 092009_ingTerra Vivos
 

Plus de Terra Vivos (15)

VivosSouthAmerica
VivosSouthAmericaVivosSouthAmerica
VivosSouthAmerica
 
vivossurvivalreport
vivossurvivalreportvivossurvivalreport
vivossurvivalreport
 
Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012
Validation of the Q - Preven HIV 1   2 DBS Immunoenzyme Kit REPORT FIN 11012012Validation of the Q - Preven HIV 1   2 DBS Immunoenzyme Kit REPORT FIN 11012012
Validation of the Q - Preven HIV 1 2 DBS Immunoenzyme Kit REPORT FIN 11012012
 
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMOAPRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
APRESENTAÇÃO DOS PROJETOS DA AFRICA DO SUL..RESUMO
 
Reflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africaReflecting on brazil’s success how durable what lessons for south africa
Reflecting on brazil’s success how durable what lessons for south africa
 
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
 
Consultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiouConsultancy activities andrã© s.efstathiou
Consultancy activities andrã© s.efstathiou
 
Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012Q preven elisa.marketing..march 2012
Q preven elisa.marketing..march 2012
 
Company formation ..directives
Company formation ..directivesCompany formation ..directives
Company formation ..directives
 
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012Validation of the q   preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
Validation of the q preven hiv 1 + 2 dbs immunoenzyme kit report fin 11012012
 
Professional profile ase review
Professional profile ase reviewProfessional profile ase review
Professional profile ase review
 
Sales Projection --Bio Oxford
Sales Projection --Bio OxfordSales Projection --Bio Oxford
Sales Projection --Bio Oxford
 
Revista new lab artigo 6 inglês
Revista new lab artigo 6 inglêsRevista new lab artigo 6 inglês
Revista new lab artigo 6 inglês
 
Prime diagnostics
Prime diagnosticsPrime diagnostics
Prime diagnostics
 
Apresentação prime 092009_ing
Apresentação prime 092009_ingApresentação prime 092009_ing
Apresentação prime 092009_ing
 

Apresentação Prime - INGLÊS - programa de triagem (10) ALTERAÇÕES1.ppt (1.103)

  • 2. Our commitment to being recognized as the most innovating, quality and consumer- oriented distribution company of in vitro diagnostics products of Brazilian and international markets, leads us to a strategy that includes the approval of ANVISA¹ on all equipment and products offered to the market by Prime Diagnostics. Our suppliers have the main international certifications (ISO9001, ISO13485, GMP-Good Manufacturing Practices, etc.), fact that allows us to satisfy completely, or even exceed, the requirements of the market. (1) - ANVISA – Agência Nacional de Vigilância Sanitária (Vinculada ao Ministério da Saúde) (National Health Surveillance Agency (linked to the Ministry of Health) Mission
  • 3. 21 ● General Population Screening Tests ● Hepatitis B ● Hepatitis C ● Syphilis ● HIV Our Business Human blood samples collected on filter paper S&S 903
  • 4. ● Concept: Screening of large populations; ● Objective: 100% of the entire population; ● Methodology: Sample of dried blood collected on paper filter (ELISA). Business Philosophy Aiming at: Facilitating access to patients Identifying epidemiological profile
  • 5. Procedure for collecting blood on paper filter See attached sample
  • 6. Access Practicality Prevention Innovation Economy Benefits
  • 7. Access Practicality Prevention Innovation Economic • Internalization of the Epidemic • Limited need of laboratory infrastructure in remote areas • Paper filter takes the laboratory structure of urban centers that are difficult to access. Benefits
  • 8. • Easy method of sample collection -Total blood •Great solid support for antibodies •Low volume and little invasive •(50ul/spot) •Transport (non-infectious) • Easy storage at room temperature • great stability Access Practicality Prevention Innovation Economic Benefits
  • 9. Access Practicality Prevention Innovation Economic •Facilitates the diagnosis and consequently: • Immediate treatment and reduction of severe cases • Increasing opportunities of prevention • Decrease in costs with assistance Benefits
  • 10. Access Practicality Prevention Innovation Economic • This methodology can be integrated: •Urban, rural and remote population •Family health program Benefits
  • 11. Benefits Access Practicality Prevention Innovation Economy • Cost Savings Transportation Storage Equipment Material - Syringe needle -Collection tubes - Energy (no spin)
  • 12. Logistics Serum Paper Filter Extraction Syringe Lancet Preparation Centrifugal machine - Conservation Controlled Temperature (Ice) Environment Transportation Polystyrene (Ice) Envelope Professional Professionals Simple Training The Benefits of Paper Filter vs. the Serum Method
  • 13. 1. Samples of dried blood on filter paper are easy to collect, carry and store. 2. Results equivalent to those obtained using the alternative method of test on serum. 3. Excellent solution for areas without structure, or with precarious laboratory structure. 4. Studies conducted by Brazilian institutions showed that, unlike the collection method on needles, dried blood samples on paper filter remain keep their properties preserved at extreme temperature conditions as 51°C, even when combined with high humidity. Summary
  • 14. HIV infection in the population is a growing problem, especially in developing countries hit by the AIDS epidemic. The most frequent way of a child to acquire HIV infection is through his/her mother during pregnancy, at birth or through breastfeeding. The Importance of Prevention
  • 15. In the 21st century, the HIV epidemic continues out of control in many countries of the world. The Joint United Nations Program on HIV/AIDS (UNAIDS) estimates that 40 million people would be living with HIV/AIDS, five million are infected every year, of which three million would be children; of these, 500 thousand children would die as a result of the infection and 700 thousand would have acquired new infections only that year, many of them taken to death before reaching adolescence. The Importance of Prevention
  • 16. Whatever the disease, it is always better to identify it in the pre- symptomatic phase or in its early stages. This is the reason why the programs aimed at the prevention and early diagnosis of various diseases are the main objectives of current health initiatives. The main purpose of these educational and prevention initiatives is to provide all the resources necessary to disclose the information required for the reduction of infection and mortality rates. For example, the treatment of syphilis, a disease that can cause blindness or death in neonates, can be accomplished with a single dose of Benzathine Penicillin in primary cases, or up to 3 doses (one per week), in cases of secondary or latent syphilis. The Importance of Prevention
  • 17. These initiatives can be applied to: • General Screening Programs: For men and women in screening diseases, such as AIDS, Syphilis and Hepatitis B and C. The Importance of Prevention
  • 18. The importance of diagnostic tests for the detection of infectious diseases, has been widely disclosed around the world. Programs with this scope of coverage, given their magnitude, only would be possible to be implemented with the use of paper filter for the collection of samples. The Importance of Prevention
  • 19. Infectious Disease Screening Program for the Population What Prime Provides: Prime Diagnostics has been operating in the Brazilian market for more than five years, and has extensive knowledge and experience in the implementation, management and control of population screening programs intended for the detection of infectious diseases.
  • 20. Infectious Disease Screening Program What Prime Provides: 1-Automated and/or semi-automated equipment: High-tech equipment for the processing of results properly certified at the major world sanitation control agencies such as the FDA and CE. All equipment will be transferred under the lending scheme (commodato), without additional cost to the program. 2 - Technical Assistance for the maintenance and repair of equipment. Alternatives to 1 - Automated and/or semi-automated equipment: 2 – Technical Assistance Alternative consists of hiring a laboratory to conduct the tests and the same will be paid by PRIME.
  • 21. Infectious Disease Screening Program for the Population What Prime Provides: 4- Collection kit All the material necessary to the collection of blood samples (model attached). 1 - Lancet 2- Sachet Silica 3- Sachet Alcohol 4– Paper filter 5– Collecting card 6- Manual 7- Small envelope 8- Larger envelope
  • 22. Infectious Disease Screening Program for the Population • 5 - Operational Training of Sample Collection: Training of multipliers of the process in relation to the care and use of the material provided for the collection, storage, handling and transport of samples.
  • 23. Infectious Disease Screening Program for the Population What Prime Provides: 6 – Chemical and Biological Reagents: Reagents needed for the processing of samples, tested and approved by international agencies of sanitary control.
  • 24. What Prime Provides: 7 - Web-based management program: Program for remote access to web-based results, with access protected by individual password. (model attached) Login l (lowercase L) 970 Password: bio970 Infectious Disease Screening Program for the Population See example attached